Drugs

, Volume 45, Issue 3, pp 384–409 | Cite as

Mifepristone

A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential
  • Rex N. Brogden
  • Karen L. Goa
  • Diana Faulds
Drug Evaluation

Abstract

Synopsis

Mifepristone is a potent oral antiprogestogen which acts at the level of the receptor, having a high affinity for the progesterone receptor. Most of the clinical trials have studied its efficacy in the termination of early pregnancy when used in conjunction with a low dosage of a prostaglandin analogue. In these studies, mifepristone 100 to 600mg administered as a single dose or over 3 or 4 days, 36 to 48 hours before a prostaglandin analogue given vaginally, intramuscularly or orally, induced complete abortion in about 95% of women. Used alone, mifepristone is an effective cervical priming agent prior to termination of first trimester pregnancy by vacuum aspiration, and facilitates termination of second trimester pregnancy by prostaglandin by reducing the interval between the start of prostaglandin treatment and termination, the cumulative prostaglandin dosage, and the adverse effects associated with these drugs. Mifepristone can also be used to induce labour in cases of intrauterine fetal death.

Mifepristone has been shown to be an effective postcoital contraceptive with a likely emergency role, since its repeated use modifies the menstrual cycle. Pilot studies have been performed in unresectable meningioma and metastatic breast cancer, and in Cushing’s syndrome.

Mifepristone is generally well tolerated, and thus is an effective, appropriate, medical alternative to surgical termination of early pregnancy. It has as yet unexplored potential as a postcoital contraceptive and in oncology.

Pharmacodynamic Properties

Mifepristone is an orally active antiprogestogen which acts by competing with progesterone for receptor binding. It also possesses antiglucocorticoid and weak antiandrogenic activity. It is devoid of estrogenic, antiestrogenic, mineralocorticoid and antimineralocorticoid properties. Its ability to block the action of progesterone on the pregnant uterus provides a medical approach to termination of early pregnancy. In normally menstruating women, the effect of mifepristone depends on the timing of administration. When administered in the first half of the luteal phase menstrual induction occurs independently of luteolysis; mifepristone administration during the mid luteal phase produced bleeding within a few days in most women but there was a second bleed at the time of expected menses in about two-thirds. The first episode of bleeding occurred in the presence of elevated progesterone and estrogen concentrations. Administration during the late luteal phase resulted in bleeding within 1 to 3 days, shortening of the luteal phase of the treatment cycle and lengthening of the subsequent follicular phase. Administration on the first 3 days of the menstrual cycle had no effect on cycle length but when given in the late follicular phase mifepristone prolonged the follicular phase by preventing the development of a normal luteinising hormone (LH) surge and delaying a new surge for about 15 days.

In the first trimester of pregnancy, mifepristone induced uterine activity in virtually all women 36 and 48 hours after administration, and increased the sensitivity of myometrium to exogenous prostaglandin (PG). The accompanying increase in decidual PGF production is attenuated by indomethacin, but the increase in uterine activity is not, thus, mechanisms other than an increase in decidual PG production contribute to the abortifacient effect of mifepristone. Mifepristone administration also resulted in cervical ripening in pregnant women.

Single doses of mifepristone 4.5 and 6 mg/kg increase plasma levels of cortisol, adrenocorticotrophin (ACTH) and lipotrophin, and in patients with unresectable meningioma treated with 200mg daily for prolonged periods, increases in plasma cortisol, ACTH and urinary cortisol are maximal at 3 weeks, and remain unchanged thereafter. Dosages of mifepristone required to exert antiglucocorticoid effects, which are achieved by disruption of the negative pituitary feedback, are higher than those needed for antiprogestogen activity. In subjects with normal adrenal function the increase in ACTH produced by mifepristone compensates for its antiglucocorticoid activity and there have been no reports of acute adrenal insufficiency at dosages used to terminate early pregnancy.

Pharmacokinetic Properties

Following single dose administration of mifepristone 600mg to healthy female volunteers, mean maximum plasma concentrations were about 2.0 mg/L at 1.35 hours. After a 20mg dose the absolute bioavailability of mifepristone was 69%. The pharmacokinetics of mifepristone are non-linear and its volume of distribution and clearance are inversely correlated with α1 -acid glycoprotein (AAG) concentration and are time- and dose-dependent.

Mifepristone is about 98% bound to plasma proteins binding with high affinity to AAG. Mifepristone crosses the placenta; the maternal/fetal ratio in plasma for mifepristone and its monodemethylated metabolite were 9.1 and 17.1, respectively.

Metabolism occurs by successive demethylations and by hydroxylation. After administration of 600mg of tritiated mifepristone, 10% of the radioactivity was eliminated in the urine and 90% in the faeces.

Therapeutic Efficacy

Early trials of mifepristone alone at dosages of 50 to 200mg daily for 4 to 7 days reported successful termination of pregnancy in 50 to 86% of women with amenorrhoea of up to 49 days duration, with efficacy apparently related to gestational age. The maximal success rate was achieved with a single oral dose of mifepristone 600mg in pregnancies of up to 41 days of amenorrhoea. These results were not considered sufficient for large scale use of mifepristone alone as an alternative to surgical termination of pregnancy and in subsequent trials the drug was combined with a low dose of a PG analogue administered vaginally, intramuscularly or orally. When combined with the PGE1 analogues misoprostol or gemeprost, the PGE2 analogues sulprostone, meteneprost (9-methylene PGE2), or the PGF analogue PG05, complete abortion usually occurred in about 95% of women pregnant for up to 49 days. In a large study conducted in the United Kingdom, efficacy was similar when mifepristone 600mg was combined with gemeprost 1mg in pregnancies up to 63 days of amenorrhoea. Mifepristone 600mg as a single dose or over 4 days combined with gemeprost was as effective as vacuum aspiration or gemeprost alone in terminating pregnancies of up 56 days, but caused less severe pain then the PG analogue alone.

Mifepristone alone was shown to facilitate PG-induced termination of second trimester pregnancy by reducing the interval between PG administration and expulsion of the products of conception, abdominal pain, and cumulative dosage of PGE.

Administration of mifepristone 400 to 600 mg/day for 2 days induced labour and fetal expulsion following intrauterine death in the second or third trimester of pregnancy.

Cervical dilatation induced by mifepristone 200 to 600mg administered as a single dose or over 2 days, has been used prior to surgical termination of first trimester pregnancy. Cervical diameter was significantly increased and the force necessary to dilate the cervix to 8 to 10mm was significantly reduced by pretreatment with mifepristone compared with placebo and was comparable with that required after pretreatment with gemeprost or a laminaria tent. Encouraging preliminary results were obtained in the induction of labour at term.

Administration of mifepristone 600mg within 72 hours of unprotected sexual intercourse was as effective as ethinylestradiol/norgestrel and more effective than danazol in preventing pregnancy. Once-monthly administration of mifepristone 200mg 2 days after the LH surge was also apparently effective in preventing pregnancy, but administration in this manner delays onset of the next menstrual period in about 40% of patients.

When mifepristone was administered immediately before expected menses, as a postcoital contragestive agent, the success rate when related to confirmed pregnancies was about 80%.

Initial studies suggest that mifepristone may have a role in the management of endometriosis, but it appeared ineffective in alleviating symptoms of premenstrual syndrome.

Oncological studies with mifepristone 200mg daily for prolonged periods indicate a possible role for the drug in unresectable meningioma and metastatic breast cancer in postmenopausal women, but further studies are needed to determine the potential of mifepristone in these diseases.

Preliminary studies suggest that prolonged administration of mifepristone may be useful in resolving biochemical and clinical abnormalities associated with Cushing’s syndrome due to ectopic ACTH secretion or adrenal tumour.

Tolerability

Mifepristone is generally well tolerated, with uterine bleeding generally lasting about 12 days after termination of early pregnancy. Such bleeding is frequently comparable with normal menstruation and is seldom sufficient to require haemostatic curettage or blood transfusion. During the 4-hour period following PG administration, pain occurs in about 80% of women; it requires non-narcotic analgesia in about 30% with up to a further 30% needing oral or parenteral narcotic analgesia.

Long term administration leads to increased plasma levels of cortisol and ACTH.

Dosage and Administration

The dosage of mifepristone most commonly used in the termination of early pregnancy is 600mg administered as a single dose 36 or 48 hours before a low dose of a PG analogue. Qualified medical personnel and resuscitation equipment should be immediately available during the 4-hour period following PG administration. All rhesus negative women should receive anti-D immunoglobulin at the time of PG administration, as in surgical pregnancy termination.

Keywords

Early Pregnancy Mifepristone Cervical Dilatation Prostaglandin Analogue Trimester Pregnancy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Asch RH, Weckstein LN, Balmaceda JP, Rojas F, et al. Non-surgical expulsion of non-viable early pregnancy: a new application of RU 486. Human Reproduction 5: 481–483, 1990PubMedGoogle Scholar
  2. Aubeny E, Balieu E-E. Activité contragestive de l’association au RU 486 d’une prostaglandine active par voie orale. Comptes Rendus de l’Acadamies des Sciences Serie III Science de la Vie 312: 539–546, 1991Google Scholar
  3. Baulieu E-E. RU 486: an antiprogestin steroid with contraceptive activity in women. In Baulieu E-E & Segal SJ (Eds) The antiprogestin steroid RU 486 and human fertility control, pp. 1–25, Plenum Press, New York and London, 1985Google Scholar
  4. Balieu E-E, Segal SJ. The antiprogestin steroid RU 486 and human fertility control. Plenum Press, New York, 1985Google Scholar
  5. Baulieu E-E, Ulmann A, Philibert D. Contragestion by the antiprogestin RU 486: A novel approach to human fertility control. Symposium on fertility control today and tomorrow, Stockholm, Sept. 29–Oct. 1,1986Google Scholar
  6. Bertagna X, Bertagna C, Luton J-P, Husson JM, Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. Journal of Clinical Endocrinology and Metabolism 59: 25–28, 1984PubMedGoogle Scholar
  7. Bertagna X, Bertagna C, Laudat M-H, Husson JM, Girard F, et al. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism 63: 639–643, 1986PubMedGoogle Scholar
  8. Birgerson L, Odlind V. Early pregnancy termination with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and epostane. Fertility and Sterility 48: 565–570, 1987PubMedGoogle Scholar
  9. Cameron IT, Baird DT. Early pregnancy termination: a comparison between vacuum aspiration and medical abortion using prostaglandin (16,16 dimethyl-trans-Δ2-PGE1 methyl ester) or the antiprogestogen RU,486. British Journal of Obstetrics and Gynaecology 95: 271–276, 1988.PubMedGoogle Scholar
  10. Cameron IT, Michie AF, Baird DT. Therapeutic abortion in early pregnancy with antiprogestogen RU486 alone or in combination with prostaglandin analogue (Gemeprost). Contraception 34: 459–468, 1986PubMedGoogle Scholar
  11. Cabrol D, Bouvier D’Yvoire M, Mermet E, Cedard L, Sureau C, et al. Induction of labour with mifepristone after intrauterine fetal death. Correspondence. Lancet 2: 1019, 1985PubMedGoogle Scholar
  12. Cabrol D, Dubois C, Cronje H, Gonnet JM, Guillot M, et al. Induction of labor with mifepristone (RU 486) in intrauterine fetal death. American Journal of Obstetrics and Gynecology 163: 540–542, 1990PubMedGoogle Scholar
  13. Chang-hai H, Yong-en S, Zhi-hou Y, Guo-ging Z, Nai-xiong J, et al. Pharmacokinetic study of orally administered RU 486 in non-pregnant women. Contraception 40: 449–460, 1989Google Scholar
  14. Christensen NJ, Bygdeman M, Green K. Comparison of different prostaglandin analogues and laminaria for preoperative dilatation of the cervix in the late first-trimester abortion. Contraception 27: 51–61, 1983PubMedGoogle Scholar
  15. Chrousos GP, Laye L, Nieman LK, Kawai S, Udelsman RU, et al. Glucocorticoids and glucocorticoid antagonists: lessons from RU 486. Kidney International 34: S18–S23, 1988Google Scholar
  16. Conn M, Stewart P. Pretreatment of the primigravid uterine cervix with mifepristone 30h prior to termination of pregnancy: a double blind study. British Journal of Obstetrics and Gynaecology 98: 778–782, 1991Google Scholar
  17. Couzinet B, Le Strat N, Ulmann A, Baulieu EE, Schaison G. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). New England Journal of Medicine 315: 1565–1570, 1986PubMedGoogle Scholar
  18. Croxatto HB, Salvatierra AM, Croxatto HD, Spitz IM. Variable effects of RU486 on endometrial maintenance in the luteal phase extended by exogenous HCG. Clinical Endocrinology 31: 15–23, 1989PubMedGoogle Scholar
  19. Croxatto HB, Salvatierra AM, Romero C, Spitz IM. Late luteal phase administration of RU 486 for three successive cycles does not disrupt bleeding patterns or ovulation. Journal of Clinical Endocrinology and Metabolism 65: 1272–1277, 1987aPubMedGoogle Scholar
  20. Croxatto HB, Salvatierra AM, Romero C, Spitz IM. LAte luteal phase administration of RU 486 for three consecutive cucles does not disrupt bleeding patterns or ovulation. Journal of Clinical Endocrinology and Metabolism 65: 1272–1277, 1987bPubMedGoogle Scholar
  21. Csapo AI. The prospects of prostaglandins in post conceptional therapy. Prostaglandins 3: 245–249, 1973PubMedGoogle Scholar
  22. Delay M, Genestal M, Carrie D, Livarek B, Boudjemaa B, et al. Arret cardio-circulatoire apres administration de l’association mifepristone (Mifegyne) sulprostone (Nalador) pour interruption de grosses-se. Abstract. Archives des Maladies du Coeur et des Vaisseaux 34: 281, 1991Google Scholar
  23. Deraedt R, Bonnat C, Busigny M, Chatelet P, Cousty C, et al. Pharmacokinetics of RU 486. In Baulieu E-E & Segal SJ (Eds) The antiprogesterone steroid RU 486 and human fertility control, pp. 103–122. Plemnn Press, New York, 1985Google Scholar
  24. Dixon GW, Schlesselman JJ, Ory HW, Blye RP. Ethinylestradiol and conjugated estrogens as postcoital contraceptives. Journal of the American Medical Association 244: 1336–1339, 1980PubMedGoogle Scholar
  25. Dubois C, Ulmann A, Baulieu E-E. Contragestion with late luteal administration of RU 486 (mifepristone). Fertility and Sterility 50: 593–596, 1988PubMedGoogle Scholar
  26. Frydman R, Lelaider C, Baton-Saint-Mleux C, Fernandez H, Vital M, et al. Labour induction in women at term with mifepristone (RU 486): a double-blind, randomised, placebo-controlled study. Obstetrics and Gynecology 80: 972–975, 1992PubMedGoogle Scholar
  27. Frydman R, Taylor S, Ulmann A. Transplacental passage of mifepristone. Correspondence. Lancet 2: 1252, 1985PubMedGoogle Scholar
  28. Gaillard RC, Riondel A, Muller AF, Herrmann W, Baulieu EE. RU486: A steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system, at a specific time of day. Proceedings of the National Academy of Sciences 81: 3879–3882, 1984Google Scholar
  29. Garzo VG, Liu J, Ulmann A, Baulieu E, Yen SSC. Effects of an antiprogesterone (RU 486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 66: 508–517, 1988PubMedGoogle Scholar
  30. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Postcoital contraception with mifepristone. Lancet 337: 1414–1415, 1991PubMedGoogle Scholar
  31. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Mifepristone(RU 486) compared with high dose estrogen and proges-togen for emergency postcoital treatment. New England Journal of Medicine 327: 1041–1044, 1992PubMedGoogle Scholar
  32. Gordon AJ, Calder AA. Oestradiol applied locally to ripen the unfavourable cervix. Lancet 2: 1319–1321, 1977PubMedGoogle Scholar
  33. Gottlieb C, Bygdeman M. The use of antiprogestin (RU 486) for termination of second trimester pregnancy. Acta Obstetricia et Gynecologica Scandinavica 70: 199–203, 1991PubMedGoogle Scholar
  34. Gravanis A, Schaison G, George M, de Brux J, Satyaswaroop PG, et al. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 60: 156–163, 1985PubMedGoogle Scholar
  35. Grimaldi B, Hamberger C, Tremblay D, Barre J, Tillement JP. In vitro Study of the binding of RU 486 and RU 42633 to human serum proteins. Progress in Clinical Biological Research 300: 445–448, 1989Google Scholar
  36. Grimes DA, Bernstein L, Lacarra M, Shoupe D, Mishell Jr DR. Predictors of failed attempted abortion with the antiprogestin mifepristone (RU 486). American Journal of Obstetrics and Gynecology 162: 910–917, 1990PubMedGoogle Scholar
  37. Grimes DA, Mishell Jr DR, Shoupe D, Lacarra M. Early abortion with a single dose of the antiprogestin RU-486. American Journal of Obstetrics and Gynecology 158: 1307–1312, 1988PubMedGoogle Scholar
  38. Grimes DA, Schultz KF, Cates W. Prevention of uterine perforation during curettage abortion. Journal of the American Medical Association 251: 2108–2111, 1984PubMedGoogle Scholar
  39. Grunberg SM. The role of progesterone receptors in meningioma. In Muggia FM (Ed) New drugs, concepts and results in cancer chemotherapy, pp. 127–137, Kluwer Academic Publishers, Boston, 1992Google Scholar
  40. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. Journal of Neurosurgery 74: 861–866, 1991PubMedGoogle Scholar
  41. Grunberg SM, Spitz IM, Demers L, Kletzky O, Dubois C, et al. Effect of chronic administration of RU486 on thyroid function. Abstract. Clinical Research 38: 585a, 1990Google Scholar
  42. Gupta JK, Johnson N. Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix. Lancet 335: 1238–1240, 1990PubMedGoogle Scholar
  43. Gupta JK, Johnson N. Should we use prostaglandins, tents or progesterone antagonists for cervical ripening before first trimester abortion?. Contraception 46: 489–497, 1992PubMedGoogle Scholar
  44. Haak HR, de Keizer RJW, Hagenouw-Taal JCW, van Seters AP, Vielvoye GJ, et al. Successful mifepristone treatment of recurrent, inoperable meningioma. Lancet 336: 124–125, 1990aPubMedGoogle Scholar
  45. Haak HR, de Keizer RJW, Hagenouw-Taal JCW, van Seters AP, Vielvoye GJ, et al. Response of meningioma to mifepristone. Abstract. European Journal of Cancer 26: 172, 1990bGoogle Scholar
  46. Heikinheimo O. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. Journal of Steroid Biochemistry and Molecular Biology 32: 21–25, 1989Google Scholar
  47. Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, et al. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. Journal of Steroid Biochemistry 26: 279–284, 1987bPubMedGoogle Scholar
  48. Heikinheimo O, Lähteenmäki PLA, Koivunen E, Shoupe D, Croxatto H, et al. Metabolism and serum binding of RU 486 in women after various single doses. Human Reproduction 2: 379–385, 1987aPubMedGoogle Scholar
  49. Heikinheimo O, Tevilin M, Shoupe D, Croxatto H, Lähteenmäki P. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. Contraception 34: 613–624, 1986PubMedGoogle Scholar
  50. Heikinheimo O, Ylikorkala O, Turpeinen U, Lähteenmäki P. Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486. Acta Endocrinologica (Copenhagen) 123: 298–304, 1990Google Scholar
  51. Henrion R. RU 486 abortions. Nature 110: 338, 1989Google Scholar
  52. Henshaw RC, Templeton AA. Pre-operative cervical preparation before first trimester vacuum aspiration: a randomized controlled comparison between gemeprost and mifepristone (RU 486). British Journal of Obstetrics and Gynaecology 98: 1025–1030, 1991PubMedGoogle Scholar
  53. Henshaw RC, Templeton AA. Mifepristone: separating fact from fiction. Drugs 44: 531–536, 1992PubMedGoogle Scholar
  54. Hill NCW, Ferguson J, MacKenzie IZ. The efficacy of oral mifepristone (RU 38,486) with a prostaglandin E1 analog vaginal pessary for the termination of early pregnancy: complications and patient acceptability. American Journal of Obstetrics and Gynecology 162: 414–417, 1990aPubMedGoogle Scholar
  55. Hill NCW, Rivera J, Lopez Bernai A, Mackenzie IZ. The effect of RU 38,486 on progesterone and oestrogen receptor concentrations in the decidua and placenta in early pregnancy. Human Reproduction 5: 464–467, 1990bPubMedGoogle Scholar
  56. Hill NCW, Selinger M, Ferguson J, MacKenzie IZ. Transplacental passage of mifepristone and its influence on maternal and fetal steroid concentrations in the second trimester of, pregnancy. Human Reproduction 6: 458–462, 1991PubMedGoogle Scholar
  57. Hingorani V, Malhotra U, Kumar S, Saraya L, Sunesh K, et al. An antiprogestin steroid and PGE2 for an early pregnancy termination. Acta Obstetricia et Gynecologica Scandinavica 149 (Suppl.): 25–29, 1989Google Scholar
  58. Husson J-M, Psychoys A, Dubois C, Ulmann A. Antiprogestins in fertility control: pharmacological and clinical outlines of RU 486. In Matsumoto S (Ed) Advances in fertility control, 2: 27–39, Excerpta Medica, Tokyo, 1988Google Scholar
  59. Johnson N, Bryce FC. Could antiprogesterones be used as alternative cervical ripening agents?. American Journal of Obstetrics and Gynecology 162: 688–690, 1990PubMedGoogle Scholar
  60. Ji G, Gen-Mei Q, Yu-Ming W, Muzh-En W, Shu-Rong Z, et al. Pregnancy interruption with RU 486 in combination with dl-15-methyl-prostaglandin-F2α-methylester: the Chinese experience. Contraception 38: 675–683, 1988Google Scholar
  61. Kawai S, Nieman LK, Brandon DD, Udelsman R, Loriaux DL, et al. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. Journal of Pharmacology and Experimental Therapeutics 241: 401–406, 1987PubMedGoogle Scholar
  62. Kettel LM, Liu JH, Murphy AA, Ulmann A, Mortola JF, et al. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertility and Sterility 56: 402–407, 1991PubMedGoogle Scholar
  63. Klijn JGM, de Jong FH, Bakker GH, Lamberts WJ, Rodenburg CJ, et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Research 49: 2851–2856, 1989PubMedGoogle Scholar
  64. Kovacs L, Sas M, Resch BA, Ugocsai G, Swahn ML, et al. Termination of very early pregnancy by RU 486 — an antiprogestational compound. Contraception 29: 399–410, 1984PubMedGoogle Scholar
  65. Lähteenmäki P, Heikinheimo O, Croxatto H, Spitz I, Shoupes D, et al. Pharmacokinetics and metabolism of RU 486. Journal of Steroid Biochemistry and Molecular Biology 27: 859–863, 1987Google Scholar
  66. Lähteenmäki P, Rapeli T, Kääriäinen M, Alfthan H, Ylikorkala O. Late postcoital treatment against pregnancy with antiprogesterone RU 486. Fertility and Sterility 50: 36–38, 1988PubMedGoogle Scholar
  67. Lamberts WJ, Koper JW, de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU 486). Journal of Clinical Endocrinology and Metabolism 73: 187–191, 1991PubMedGoogle Scholar
  68. Lamberts SWJ, Tanghe HLJ, Avezaat CJJ, Braakman R, Wijngaarde R, et al. Mifepristone (RU 486) treatment of meningiomas. Journal of Neurology, Neurosurgery, and Psychiatry 55: 486–490, 1992PubMedGoogle Scholar
  69. Lefebvre Y, Proulx L, Elie R, Poulin O, Lanza E. The effects of RU-38486 on cervical ripening. American Journal of Obstetrics and Gynecology 162: 61–65, 1990PubMedGoogle Scholar
  70. Lefebvre Y, Proulx L, Elie R, Poulin O, Lanza E. The effects of RU-38486 on cervical ripening. American Journal of Obstetrics and Gynecology 162: 61–65, 1990PubMedGoogle Scholar
  71. Legarth J, Peen UBS, Michelsen JW. Mifepristone or vacuum aspiration in termination of early pregnancy. European Journal of Obstetrics, Gynecology and Reproductive Biology 41: 91–96, 1991Google Scholar
  72. Li T-C, Rogers AW, Dackery P, Lenton EA, Thomas P, et al. The effects of progesterone blockade in the luteal phase of normal fertile women. Fertility and Sterility 50: 732–742, 1988PubMedGoogle Scholar
  73. Lim BH, Lees DAR, Bjornsson S, Lunan CB, Conn MR, et-al. Normal development after exposure to mifepristone in early pregnancy. Lancet 336: 257–258, 1990PubMedGoogle Scholar
  74. Maria B, Stampf F, Goepp A, Dubois C. Termination of early pregnancy through a combination of the antiprogestin and prostaglandin analogue. European Journal of Obstetrics, Gynecology and Reproductive Biology 37: 35–40, 1990Google Scholar
  75. Maria B, Stampf F, Goepp A, Ulmann A. Termination of early pregnancy by a single dose of mifepristone (RU 486), a progesterone antagonist. European Journal of Obstetrics, Gynecology and Reproductive Biology 28: 249–225, 1988aGoogle Scholar
  76. Maria B, Chaneac M, Stampf F, Ulmann A. Interruption précoce de la grossesse par un stéroide antiprogestérone: la mifepristone (RU 486), Journal de Gynecologie, Obstetrique, et Biologie de la Reproduction 17: 1089–1094, 1988bGoogle Scholar
  77. Mishell Jr DR, Shoupe D, Brenner PF, Lacarra M, Horenstein J, et al. Termination of early gestation with the anti-progestin steroid RU 486: medium versus low dose. Contraception 35: 307–321, 1987PubMedGoogle Scholar
  78. Moguilewsky M, Philibert D. Biochemical Profile of RU 486 in Baulieu E & Segal SJ (Eds) The antiprogestin steroid RU 486 and human fertility control pp. 87–96, Plenum Press, New York, 1985Google Scholar
  79. Murphy AA, Kettel LM, Morales A, Yen SSC. Response of uterine fibroids to the antiprogesterone RU 486: A pilot study. Abstract. Fertility and Sterility Program (Suppl.): S31, 1991Google Scholar
  80. Nagoshi K, Hayashi N, Sekiba K. Automated direct assay system for RU38486, an antiprogesterone-anti-glucocorticoid agent, and its metabolites using high performance liquid chromato-graphy. Acta Medica Okayama 45: 81–87, 1991PubMedGoogle Scholar
  81. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, et al. Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. Journal of Clinical Endocrinology and Metabolism 61: 536–540, 1985PubMedGoogle Scholar
  82. Norman JE, Thong KJ, Baird DT. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 338: 1233–1236, 1991aPubMedGoogle Scholar
  83. Norman JE, Kelly RW, Baird DT. Uterine activity and decidual prostaglandin production in woman in early pregnancy in response to mifepristone with or without indomethacin in vivo. Human Reproduction 6: 740–744, 1991bPubMedGoogle Scholar
  84. Norman JE, Thong KJ, Rodger MW, Baird DT. Medical abortion in women of ⩽56 days amenorrhoea: a comparison between gemeprost (a PGE1 analogue) alone and mifepristone and gemeprost. British Journal of Obstetrics and Gynaecology 99: 601–606, 1992PubMedGoogle Scholar
  85. Padayachi T, Norman RJ, Moodley J, Heyns A. Mifepristone and induction of labour in second half of pregnancy. Correspondence. Lancet 1: 647, 1988PubMedGoogle Scholar
  86. Padayachi T, Moodley J, Norman RJ, Heyns A. Termination of pregnancy with mifepristone after intra-uterine death. South African Medical Journal 75: 540–542, 1989PubMedGoogle Scholar
  87. Permezel JM, Lenton EA, Roberts I, Cooke ID. Acute effects of progesterone and the antiprogestin RU486 on gonadotropin secretion in the follicular phase of the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 68: 960–965, 1989PubMedGoogle Scholar
  88. Philibert D, Deraedt R, Teutsch G. RU 38486: a potent antig-lucocorticoid in vivo. Abstract 1463. International Congress of Pharmacology, Tokyo, Japan, 1981Google Scholar
  89. Pons J-C, Imbert M-C, Elefant E, Roux C, Herschkorn et al. Development after exposure to mifepristone in early pregnancy. Correspondence. Lancet 338: 763, 1991PubMedGoogle Scholar
  90. Pons J-C, Papiernik E. Mifepristone teratogenicity. Lancet 338: 1332–1333, 1991PubMedGoogle Scholar
  91. Pons JC, Rais S, Diochin P, Frydman R. RU 486 (mifepristone) et interruption volontaire ed grossesse pour motif therapeutique an deuxieme et troisieme trimestre. Journal de Gynecologie, Obstetrique, et Biologie de la Reproduction 21: 255–257, 1992Google Scholar
  92. Punnonen R, Kuurne T. Estrogen and progestin receptors in in-tracranial tumors. Hormone Research 27: 74–77, 1987PubMedGoogle Scholar
  93. Radestad A, Bygdeman M, Green K. Induced cervical ripening with mifepristone (RU 486) and bioconversion of arachidonic acid in human pregnant uterine cervix in the first trimester. Contraception 41: 283–292, 1990PubMedGoogle Scholar
  94. Rodger MW, Baird DT. Pretreatment with mifeprislone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. British Journal of Obstetrics and Gynaecology 97: 41–45, 1990PubMedGoogle Scholar
  95. Rodger MW, Baird DT. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet 2: 1415–1418, 1987PubMedGoogle Scholar
  96. Rodger MW, Baird DT. Blood loss following induction of early abortion using mifepristone (RU486) and a prostaglandin analogue (gemeprost). Contraception 40: 439–447, 1989PubMedGoogle Scholar
  97. Rodger MW, Logan AF, Baird DT. Induction of early abortion with mifepristone (RU486) and two different doses of prostaglandin pessary (Gemeprost). Contraception 39: 497–502, 1989PubMedGoogle Scholar
  98. Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J. The antiprogestin RU 486 in advanced breast cancer: preliminary clinical trial. Bulletin du Cancer 74: 455–461, 1987PubMedGoogle Scholar
  99. Schaison G, George M, Lestrat N, Reinberg A, Baulieu EE. Effects of the antiprogesterone steroid RU 486 during mid luteal phase in normal women. Journal of Clinical Endocrinology and Metabolism 61: 484–489, 1985PubMedGoogle Scholar
  100. Schmidt PJ, Nieman LK, Grover GN, Muller KL, Merriam GR, et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. New England Journal of Medicine 324: 1174–1179, 1991PubMedGoogle Scholar
  101. Schultz KF, Grimes DA, Cates W. Measures to prevent cervical injury during suction curettage abortion. Lancet 1: 1182–1185, 1983Google Scholar
  102. Shangchun W, Ji G, Yuming W, Muzhen W, Huimin F, et al. Clinical trial on termination of early pregnancy with RU 486 in combination with prostaglandin. Contraception 46: 203–210, 1992Google Scholar
  103. Shoupe D, Mishell DR, Lahteenmaki P, Heikinheimo O, Birgerson L, et al. Effects of RU 486 in normal women. Single-dose administration in the mid luteal phase. American Journal of Obstetrics and Gynecology 157: 1415–1420, 1987aPubMedGoogle Scholar
  104. Shoupe D, Mishell DR, Page MA, Madkour H, Spitz IM, et al. Effects of the antiprogesterone RU 486 in normal women. Administration in the late follicular phase. American Journal of Obstetrics and Gynecology 157: 1421–1426, 1987bPubMedGoogle Scholar
  105. Shu-rong Z. RU 486 (mifepristone): clinical trials in China. Acta Obstetricia et Gynecologica Scandinavica 149: 19–23, 1989Google Scholar
  106. Silvestre L, Dubois C, Renault M, Rezvani Y, Baulieu E-E, et al. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. New England Journal of Medicine 322: 645–648, 1990PubMedGoogle Scholar
  107. Sitruk-Ware R, Thalabard J-C, De Plunkett TL, Lewin F, Epelboin S, et al. The use of the antiprogestin RU486 (mifepristone). Contraception 41: 221–243, 1990PubMedGoogle Scholar
  108. Skafar DF. Differences in the binding mechanism of RU486 and progesterone to the progesterone receptor. Biochemistry 30: 10829–10832, 1991PubMedGoogle Scholar
  109. Somell C, Olund A. Induction of abortion in early pregnancy with mifepristone. Gynecologic and Obstetric Investigation 29: 13–15, 1990PubMedGoogle Scholar
  110. Sorbette F, Delay M, Genestal M, Jonda MF, Carrie D, et al. Arrêt cardio-circulatoire au cours de l’association mifépri-stone-sulprostone pour interruption de grossesse. Therapie 46: 387–392, 1991PubMedGoogle Scholar
  111. Stuenkel CA, Liu JH, Gorzo VG, Yen SSC, Morris S. Effects of the antiprogesterone RU 486 in the early follicular phase of the menstrual cycle. Fertility and Sterility 53: 642–646, 1990PubMedGoogle Scholar
  112. Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. British Journal of Obstetrics and Gynaecology 95: 126–134, 1988PubMedGoogle Scholar
  113. Swahn ML, Gottlieb C, Green K, Bygdeman M. Oral administration of RU 486 and 9-methylene PGE2 for termination of early pregnancy. Contraception 41: 461–473, 1990PubMedGoogle Scholar
  114. Swahn M-L, Bygdeman M. Termination of early pregnancy with RU 486 (mifepristone) in combination with a prostaglandin analogue (Sulprostone). Acta Obstetricia et Gynecologica Scandinavica 68: 293–300, 1989PubMedGoogle Scholar
  115. Swahn ML, Gemzell K, Bygdeman M. Contraception with mifepristone. Correspondence. Lancet 338: 942–943, 1991PubMedGoogle Scholar
  116. Thong KJ, Baird DT. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy. Contraception 46: 11–17, 1992PubMedGoogle Scholar
  117. UK Multicentre Trial. The efficacy and tolerance of mifepristone and prostaglandin in first trimester termination of pregnancy. British Journal of Obstetrics and Gynaecology 97: 480–486, 1990Google Scholar
  118. Ulmann A. Uses of RU 486 for contragestion: an update. Contraception 36 (Suppl.): 27–31, 1987PubMedGoogle Scholar
  119. Ulmann A, Silvestre L, Chemama L, Rezvaní Y, Renaut M, et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Acta Obstetricia et Gynaecologica Scandinavica 71: 278–283, 1992Google Scholar
  120. Ulmann A, Teutsch G, Philibert D. RU 486. Scientific American 262: 42–48, 1990PubMedGoogle Scholar
  121. Ulmsten U, Kirstein-Pedersen A, Stenberg P, Wingerup L. A new gel for intracervical application of prostaglandin E2. Acta Obstetricia et Gynecologica Scandinavica 84 (Suppl.): 19–21, 1979Google Scholar
  122. Urquhart DR, Bahzad C, Templeton AA. Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy. Human Reproduction 4: 202–203, 1989PubMedGoogle Scholar
  123. Urquhart DR, Templeton AA. Mifepristone (RU 486) and second-trimester termination. Correspondence. Lancet 2: 1405–1406, 1987PubMedGoogle Scholar
  124. Urquhart DR, Templeton AA. Mifepristone (RU 486) for cervical priming prior to surgically induced abortion in the late first trimester. Contraception 42: 191–199, 1990aPubMedGoogle Scholar
  125. Urquhart DR, Templeton AA. The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. Human Reproduction 5: 883–886, 1990bPubMedGoogle Scholar
  126. van der Lely A-J, Foeken K, van der Mast RC, Lamberts SWJ. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Annals of Internal Medicine 114: 143–144, 1991PubMedGoogle Scholar
  127. van Santen MR, Haspels AA. Postcoital luteal contragestion by an antiprogestin (mifepristone, RU 486) in 62 women. Contraception 35: 423–431, 1987PubMedGoogle Scholar
  128. Vervest HAM, Haspels AA. Preliminary results with the antiprogestational compound RU-486 (mifepristone) for interruption of early pregnancy. Fertility and Sterility 44: 627–632, 1985PubMedGoogle Scholar
  129. Walt RP. Misoprostol for the treatment of peptic ulcer and an-tiinflammatory drug-induced gastroduodenal ulceration. New England Journal of Medicine 327: 1575–1580, 1992PubMedGoogle Scholar
  130. Webb AMC. Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception 7: 271–279, 1991PubMedGoogle Scholar
  131. Webb AMC, Russell J, Elstein M. Comparision of Yuzpe regimen, dariazol, and mifepristone (RU 486) in oral postcoital contraception. British Medical Journal 305: 927–931, 1992PubMedGoogle Scholar
  132. Whittle IR, Hawkins RA, Miller JD. Sex hormone receptors in intracranial tumours and normal brain. European Journal of Surgical Oncology 13: 303–307, 1987PubMedGoogle Scholar
  133. Wolf JP, Hsiu JG, Anderson TL, Ulmann A, Baulieu EE, et al. Noncompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and proliferative action of estradiol on endometrium in castrated monkeys. Fertility and Sterility 52: 1055–1060, 1989PubMedGoogle Scholar
  134. World Health Organization. Randomised comparison of different prostaglandin analogues and laminaria tent for preoperative cervical dilatation. Contraception 34: 237–251, 1986Google Scholar
  135. World Health Organization. The use of mifepristone (RU 486) for cervical preparation in first trimester pregnancy termination by vacuum aspiration. British Journal of Obstetrics and Gynaecology 97: 260–266, 1990Google Scholar
  136. World Health Organization. Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. Fertility and Sterility 56: 32–40, 1991Google Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Rex N. Brogden
    • 1
  • Karen L. Goa
    • 1
  • Diana Faulds
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations